Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com 2 Small-Cap Biotechs That Could Reward Patient InvestorsAuthored by Chris Markoch. Publication Date: 12/12/2025. 
Article Highlights - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. Still, if you’re considering the small-cap biotech sector, patience is essential. Many of these companies remain in the clinical stage and have no commercially available drugs or therapeutics. That also means negative earnings (they are not yet profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage program. If your retirement strategy involves "picking the right stocks," you're one crash away from disaster…
A hedge fund legend who made $95 million in profits during a crash has a different way.
He's using 18-digit codes to "skim" the market without buying stocks.
And his followers have seen an 84%-win rate. Click here to see how he does it Even when a product advances through trials, profitability can be years away. Only after reaching meaningful commercial milestones do companies typically attract analyst coverage and institutional investment. Getting in on one of these medical stocks that breaks out can feel like hitting the lottery. Investors can see 3x, 5x, or even 10x returns quickly — while others never pan out. This is why many investors who pursue penny stocks spread a lump sum across many biotech names. If it truly is a numbers game, diversification can help manage risk. With that in mind, here are two small-cap biotech stocks that carry significant risk but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this space, Mainz Biomed already has a commercial product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading digital-health provider in Germany. With over 60,000 new colorectal cancer cases annually in Germany, the addressable market is sizable. Mainz Biomed is also developing a non-invasive, blood-based screening test for early pancreatic cancer. The company reported positive topline results in October, but commercial approval is still years away. The risks are material. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. Accordingly, the company included “going concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf offering to raise capital. That financing activity has helped support the MYNZ share price and reduce immediate delisting risk for now. The company must ramp revenue quickly to change its financial trajectory. If it succeeds, however, even a relatively small investment could deliver a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another small- to micro-cap biotech offering a potentially disruptive approach to antiviral treatment, but it also carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and attract viruses to bind with them, neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could introduce a fundamentally new approach to treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to continue development. Recent filings indicate limited cash on hand, so investors should expect the possibility of future dilution. Still, if even one candidate advances into clinical development and proves effective, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC stock represents a genuine moonshot in the antiviral space.
| 
